Figure 2.

CD95 expression is associated with an EMT signature. (a) CD95 expression in tumour samples from pancreatic cancer patients grouped by subtype (classical PDA, n=11; exocrine-like PDA, n=14; QM-PDA, n=11) (*P<0.05, **P<0.01, Wilcoxon's rank-sum test). (b) GSEA. Horizontal axis represents ranking of genes according to their differential expression between CD95^high and CD95^low samples as shown in (c). Black bars on the lower part of the plot represent genes from EMT transition gene signature (ES=0.5031388, P-value <1e10−3). (c) Empirical Bayes moderated t-statistics of differential expression between groups of CD95 expression high and low. Known EMT (ZEB2, VIM, TGFB1 and SNAI2) and differentiation (DSP, OCLN and CDH1) genes are highlighted. CD95 is also highlighted scoring the highest in the ranking. (d) CD95 expression in PDAC-CSC lines derived from four patients (A–D) as measured by flow cytometry. (e) mRNA expression analysis of EMT and pancreatic differentiation markers from PDAC-CSC lines derived from Patients A–D. CD95-positive and -negative cells were FACS (fluorescence-activated cell sorting) sorted and mRNA was extracted for quantitative PCR (qPCR) analysis